Ikarian Capital, LLC Tg Therapeutics, Inc. Transaction History

Ikarian Capital, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$8.36 - $26.5 $272,092 - $862,495	32,547 New	32,547 $272,000
Q2 2022 Aug 12, 2022	SELL	$3.74 - $10.66 $8,572 - $24,432	-2,292 Closed	0 $0
Q1 2022 May 13, 2022	SELL	$7.81 - $20.45 $768,871 - $2.01 Million	-98,447 Reduced 97.72%	2,292 $21,000
Q4 2021 Feb 14, 2022	BUY	$15.2 - $35.51 $1.53 Million - $3.58 Million	100,739 New	100,739 $1.91 Million
Q1 2020 May 15, 2020	SELL	$7.14 - $15.99 $2.26 Million - $5.06 Million	-316,200 Closed	0 $0
Q4 2019 Jan 31, 2020	BUY	$5.1 - $11.2 $1.61 Million - $3.54 Million	316,200 New	316,200 $3.51 Million

345

87.6M

2.35M

1.7M

Ticker TGTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 145,274,000
Market Cap $4.86B
Description
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...

Get notified when there are updates to the investment portfolio of Ikarian Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Ikarian Capital, LLC with notifications on news.